Lanadelumab and Cardiovascular Risk: Findings From the Phase 3 HELP Study

Journal of Allergy and Clinical Immunology - United States
doi 10.1016/j.jaci.2018.12.138
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV